Drugs / Crizotinib
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (8) | US (FDA) | XALKORI | — | 2013-11-20 – 2023-09-07 | fda.gov ↗ |
| Approved | EU (EMA) | Xalkori | — | 2012-10-23 | europa.eu ↗ |
| Approved | US (FDA) | XALKORI | — | 2011-08-26 | fda.gov ↗ |
Trials 101 · started per year
today
US approved 2011
EU approved 2012
1
3
8
6
9
8
13
13
9
4
4
8
7
2
1
1
1
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02277457 | Sep 2015 → Jun 2021 | non-small cell lung carcinoma | University of Michigan Rogel Cancer Center | Withdrawn | No outcome recorded |
| Phase 133 trials | ||||||
| Phase 1 | NCT04693468 | Dec 2020 → Dec 2027 expected | high grade malignant neoplasm, metastatic malignant neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03978143 | Jun → Oct 2019 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03137134 | Jun → Sep 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02511184 | Oct 2015 → Dec 2017 | — | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT02510001 | Nov 2014 → Dec 2018 | colorectal cancer | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT02270034 | Aug 2014 → Oct 2020 | brain glioblastoma | Grupo Español de Investigación en Neurooncología | Completed | No outcome recorded |
| Phase 1 | NCT02207504 | Aug 2014 → Feb 2018 | castration-resistant prostate carcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02074878 | Jun 2014 → May 2017 | breast cancer | Mothaffar Rimawi | Terminated | No outcome recorded |
| Phase 1 | NCT01999972 | Feb 2014 → Feb 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01998126 | Dec 2013 → May 2017 | non-small cell lung carcinoma | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT02006277 | Dec 2013 → Mar 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01606878 | Apr 2013 → Dec 2018 | anaplastic large cell lymphoma, childhood malignant neoplasm, neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT01744652 | Mar 2013 → Mar 2019 | — | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01644773 | Nov 2012 → Mar 2018 | diffuse intrinsic pontine glioma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01576406 | Jul 2012 → Jun 2016 | cancer of unknown primary site | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01549574 | May 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01579994 | Apr 2012 → Dec 2020 | lung cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01548144 | Apr 2012 → Aug 2021 | cancer of unknown primary site | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT01531361 | Feb 2012 → Jan 2021 | metastatic malignant neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01441388 | Dec 2011 → Nov 2013 | glioblastoma, hepatocellular carcinoma, renal cell carcinoma | Pfizer | Withdrawn | No outcome recorded |
| Phase 1 | NCT01419041 | Nov 2011 → Aug 2012 | impaired renal function disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01441128 | Sep 2011 → Feb 2014 | adenocarcinoma, large cell carcinoma, non-small cell lung carcinoma, squamous cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT01121588 | Mar 2011 → Sep 2023 | cancer | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT01297595 | Mar → Apr 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01250730 | Dec 2010 → Jan 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01121575 | Aug 2010 → Feb 2014 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01168934 | Aug → Sep 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01147055 | Jul → Oct 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01149785 | Jul → Sep 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01082380 | Mar → Apr 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00965731 | Jan 2010 → Dec 2011 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00939731 | Jul → Aug 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00585195 | Apr 2006 → Jul 2020 | anaplastic large cell lymphoma, non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT04292119 | May 2020 → Dec 2022 | non-small cell lung carcinoma, refractory malignant neoplasm | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03947385 | Jun 2019 → Jan 2027 expected | colorectal cancer, cutaneous melanoma, uveal melanoma | IDEAYA Biosciences | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02584634 | Dec 2015 → Feb 2021 | non-small cell lung carcinoma | Pfizer | Terminated | No outcome recorded |
| Phase 1/2 | NCT02574078 | Nov 2015 → Apr 2020 | non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT01712217 | Oct 2012 → Dec 2016 | non-small cell lung carcinoma | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00939770 | Sep 2009 → Dec 2018 | anaplastic large cell lymphoma, neuroblastoma, refractory malignant neoplasm | Children's Oncology Group | Completed | No outcome recorded |
| Phase 244 trials | ||||||
| Phase 2 | NCT06563999 | Nov 2024 → Nov 2027 expected | lung carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT05725200 | Sep 2022 → Dec 2038 expected | colorectal cancer | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05014464 | Nov 2021 → Jun 2026 overdue | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04423185 | Aug 2020 → Jul 2026 overdue | — | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT04322890 | Apr 2020 → Dec 2026 expected | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04322578 | Mar 2020 → Mar 2025 | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04644432 | Mar 2020 → Sep 2022 | renal cell carcinoma | Herlev and Gentofte Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04283669 | Feb 2020 → Feb 2025 | NF2-related schwannomatosis, acoustic neuroma | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT04084717 | Dec 2019 → Dec 2024 | non-small cell lung carcinoma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT04193007 | Dec 2019 → Dec 2021 | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Second Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
| Phase 2 | NCT04030429 | Sep 2019 → Jun 2025 | endometrial cancer | National Cheng-Kung University Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT03737994 | Jul 2019 → Jul 2021 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT03574402 | Jul 2018 → Dec 2022 | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Unknown | No outcome recorded |
| Phase 2 | NCT03297606 | Mar 2018 → Dec 2026 expected | non-Hodgkin lymphoma, plasma cell myeloma | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 2 | NCT03088930 | Dec 2017 → Jan 2021 | non-small cell lung carcinoma | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT02788201 | Mar 2017 → Oct 2019 | urinary bladder cancer, urothelial carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT03768375 | Nov 2016 → Dec 2020 | extrahepatic bile duct carcinoma, gallbladder cancer | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 2 | NCT02612194 | Sep 2016 → Sep 2019 | ureter neoplasm, urethra neoplasm, urinary bladder neoplasm | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT02925234 | Aug 2016 → Sep 2027 expected | cancer | The Netherlands Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06357975 | Jul 2016 → Nov 2022 overdue | adult lymphoma, plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02761057 | Jul 2016 → Oct 2023 | papillary renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT06360575 | Jul 2016 → Nov 2022 overdue | adult lymphoma, plasma cell myeloma, refractory malignant neoplasm | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02836847 | Jul 2016 → Dec 2019 | cholangiocarcinoma, gallbladder cancer | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 2 | NCT02946359 | Jul 2016 → Oct 2017 | lung adenocarcinoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02638428 | Dec 2015 → Dec 2021 | childhood acute myeloid leukemia | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02465060 | Aug 2015 → Dec 2026 expected | breast carcinoma, carcinoma of esophagus, cervical carcinoma, colon carcinoma +17 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04439253 | Aug 2015 → Mar 2020 overdue | adult lymphoma, plasma cell myeloma, refractory malignant neoplasm | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04439266 | Aug 2015 → Mar 2020 overdue | plasma cell myeloma, refractory malignant neoplasm | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02664935 | May 2015 → Nov 2023 | adenocarcinoma, non-small cell lung carcinoma, squamous cell carcinoma | University of Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT02419287 | Apr 2015 → Dec 2022 | ALK-positive anaplastic large cell lymphoma | University of Milano Bicocca | Completed | No outcome recorded |
| Phase 2 | NCT02223819 | Mar 2015 → Jul 2019 | uveal melanoma | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT02499614 | Dec 2014 → Jun 2018 | non-small cell lung carcinoma | Fondazione Ricerca Traslazionale | Unknown | No outcome recorded |
| Phase 2 | NCT02134912 | Aug 2014 → Sep 2016 | lung adenocarcinoma, lung large cell carcinoma | SWOG Cancer Research Network | Terminated | No outcome recorded |
| Phase 2 | NCT02435108 | May 2014 → Jan 2016 | — | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02183870 | May 2014 → Jul 2018 | adenocarcinoma, non-small cell lung carcinoma | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT02142036 | May 2014 → Aug 2018 | metastatic malignant neoplasm | Oslo University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01500824 | May 2014 → May 2016 | non-small cell lung carcinoma | Pfizer | Withdrawn | No outcome recorded |
| Phase 2 | NCT02101385 | Apr 2014 → Feb 2021 | breast cancer | Bryan Schneider, MD | Completed | No outcome recorded |
| Phase 2 | NCT01979536 | Nov 2013 → Mar 2021 | ALK-positive anaplastic large cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01822496 | Nov 2013 → Jun 2018 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT01945021 | Sep 2013 → Jul 2015 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT02034981 | Aug 2013 → Jun 2019 | hematopoietic and lymphoid cell neoplasm, metastatic malignant neoplasm | UNICANCER | Completed | No outcome recorded |
| Phase 2 | NCT01524926 | Sep 2012 → Dec 2017 | alveolar rhabdomyosarcoma, alveolar soft part sarcoma, anaplastic large cell lymphoma, clear cell sarcoma +2 | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT00932451 | Jan 2010 → Mar 2015 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05987332 | Oct 2023 → Jan 2027 expected | uveal melanoma | IDEAYA Biosciences | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03874273 | Feb 2019 → Feb 2021 | inflammatory myofibroblastic tumor | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Unknown | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT03194893 | Jul 2017 → Sep 2025 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02201992 | Mar 2015 → May 2036 expected | non-small cell lung carcinoma | ECOG-ACRIN Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01639001 | Sep 2012 → Jun 2015 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01154140 | Jan 2011 → Nov 2013 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00932893 | Sep 2009 → Mar 2012 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05160922 | Dec 2021 → Mar 2028 expected | anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, non-small cell lung carcinoma | Pfizer | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03672643 | Jan 2019 → Sep 2023 | — | Pfizer | Terminated | No outcome recorded |
| Phase 4 | NCT03707847 | Oct 2018 → Feb 2020 | ALK-positive anaplastic large cell lymphoma | Mingzhi Zhang | Unknown | No outcome recorded |
| Phase 4 | NCT02487316 | Jul 2015 → Nov 2017 | ALK-positive anaplastic large cell lymphoma | Jun Zhu | Withdrawn | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05792644 | Jan 2018 → May 2022 | ALK+ histiocytosis | Harbin Medical University | Completed | No outcome recorded |
| — | NCT05063058 | Jan 2016 → Nov 2019 | melanoma | Charite University, Berlin, Germany | Completed | No outcome recorded |
| — | NCT02194738 | Sep 2014 → Sep 2026 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT02824094 | — | non-small cell lung carcinoma | Pfizer | No longer available | No outcome recorded |
| — | NCT02473497 | — | neoplasm | Pfizer | No longer available | No outcome recorded |
| — | NCT03085186 | — | inflammatory myofibroblastic tumor | Jean M. Tersak, M.D. | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 19 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01125904 Background | Jun 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01970865 Background | Jan 2014 → Mar 2017 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03620643 Comparator | May 2019 → Aug 2024 | breast lobular carcinoma, gastric cancer, triple-negative breast carcinoma | Royal Marsden NHS Foundation Trust | Completed | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT06564324 Comparator | Nov 2024 → Jan 2029 expected | non-small cell lung carcinoma | Nuvation Bio Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06254599 Comparator | May 2024 → May 2026 overdue | non-small cell lung carcinoma | Shouyao Holdings (Beijing) Co. LTD | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06140836 Comparator | Dec 2023 → Mar 2026 overdue | non-small cell lung carcinoma | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06082635 Comparator | Dec 2023 → Apr 2026 overdue | non-small cell lung carcinoma | Shenzhen TargetRx Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05204628 Comparator | Feb 2022 → May 2025 | non-small cell lung carcinoma | Xuanzhu Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04603807 Comparator | Sep 2021 → Jun 2028 expected | non-small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04009317 Comparator | Aug 2019 → Oct 2021 | non-small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04632758 Comparator | Jun 2019 → Dec 2024 | non-small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03052608 Comparator | Apr 2017 → Mar 2020 overdue | non-small cell lung carcinoma | Pfizer | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02838420 Comparator | Aug 2016 → May 2018 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02767804 Comparator | Jun 2016 → Dec 2025 overdue | non-small cell lung carcinoma | Xcovery Holdings, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02737501 Comparator | May 2016 → Jul 2020 | non-small cell lung carcinoma | Ariad Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02075840 Comparator | Aug 2014 → Feb 2017 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04356118 Background | Jun 2020 → Jun 2023 | malignant leptomeningeal tumor | Hui Bu | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02701231 Background | Nov 2015 → Dec 2020 | lung cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT00828919 Background | Mar 2003 → Aug 2023 | cancer | Pfizer | Completed | No outcome recorded |
Press releases naming this drug 14 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-01-14 | Pfizer | Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults pfizer.com ↗ |
| 2020-09-23 | Pfizer | FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma pfizer.com ↗ |
| 2018-05-29 | Pfizer | Pfizer’s XALKORI® (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications pfizer.com ↗ |
| 2017-09-11 | Pfizer | Pfizer Presents Overall Survival Data of XALKORI in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer pfizer.com ↗ |
| 2017-06-05 | Roche Global Development | Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer roche.com ↗ |
| 2017-04-10 | Roche Global Development | Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer roche.com ↗ |
| 2016-08-31 | Pfizer | XALKORI® (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer pfizer.com ↗ |
| 2016-03-11 | Pfizer | XALKORI® (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer pfizer.com ↗ |
| 2015-12-08 | Pfizer | Pfizer Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for XALKORI® (crizotinib) for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer pfizer.com ↗ |
| 2015-11-24 | Pfizer | Pfizer Receives European Approval to Expand Use of XALKORI® (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer pfizer.com ↗ |
| 2015-11-18 | Pfizer | Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI® (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) pfizer.com ↗ |
| 2015-04-21 | Pfizer | Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI® (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer pfizer.com ↗ |
| 2015-04-07 | Pfizer | Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Finalize Agreement to Co-Promote XALKORI® (crizotinib) pfizer.com ↗ |
| 2015-02-27 | Novartis Pharmaceuticals | Novartis lung cancer drug Zykadia® recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinib novartis.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 121 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | crizotinib | “Crizotinib (Pfizer, CA, USA) is an oral small-molecule RTK inhibitor that targets ALK and MET, and potentially other RTKs.” PMID 22316363 ↗ Feb 2012110“Crizotinib (Pfizer, CA, USA) is an oral small-molecule RTK inhibitor that targets ALK and MET, and potentially other RTKs.” PMID 22316363 ↗ Feb 2012 “if EGFR mutation is positive, (gefitinib, ecotinib, erlotinib）or ALK/ROS-1 positive（Crizotinib）” NCT04193007 ↗ “Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered” NCT03978143 ↗ “With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib.” NCT02701231 ↗ “MET Inhibitors (Crizotinib 250 mg 2/d, or Cabozantinib 60mg/d)” NCT05063058 ↗ “Arm B: Crizotinib monotherapy at 250 mg twice daily (BID)” NCT06564324 ↗ “Crizotinib is a medication that is taken by mouth.” NCT02074878 ↗ “ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib” NCT04356118 ↗ “Crizotinib 250 mg twice a day for 4 weeks” NCT04644432 ↗ “Clofarabine, Crizotinib, Cytarabine” NCT02788201 ↗ “Drug: Sorafenib Drug: Crizotinib” NCT03768375 ↗ “12. MET: Crizotinib” NCT02101385 ↗ “Drug: Crizotinib” NCT02511184 ↗ “Crizotinib” NCT02142036 ↗ |
| Known as | NSC-756645 | ChEMBL registry synonym — accepted as the source's own label CHEMBL601719 ↗ |
| Known as | PF-02341066 | “A Phase 1, Fixed Sequence, Cross-Over Study To Estimate The Effect Of Multiple Dose Rifampin On The Single Dose Pharmacokinetics Of Crizotinib (PF-02341066) In Healthy Volunteers” NCT01147055 ↗13“A Phase 1, Single Dose, Randomized, Cross-Over Absolute Bioavailability Study In Healthy Volunteers Comparing Oral To Intravenous Administration Of Crizotinib (PF-02341066)” NCT01168934 ↗ “Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)” NCT01121588 ↗ “Crizotinib (PF-02341066)” NCT01524926 ↗ |
| Known as | Pf-2341066 | ChEMBL registry synonym — accepted as the source's own label CHEMBL601719 ↗ |
| Known as | XALKORI | “Crizotinib (Xalkori (Registered)) Expanded Access Protocol For The Treatment Of Japanese Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or...” NCT02824094 ↗2“Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.” NCT04084717 ↗ “The marketing name of the drug is "Xalkori".” NCT02074878 ↗ |
| Action | Inhibit | “Macrophage-stimulating protein receptor inhibitor” CHEMBL601719 ↗1“targets ALK and MET” PMID 22316363 ↗ Feb 2012 |
| Modality | Small molecule | “Crizotinib (Pfizer, CA, USA) is an oral small-molecule RTK inhibitor” PMID 22316363 ↗ Feb 2012 |
| Route | Oral | “PF-02341066 is taken by mouth daily.” NCT00585195 ↗ |
| Target | ALK | “targets ALK and MET” PMID 22316363 ↗ Feb 2012 |
| Target | MET | “targets ALK and MET” PMID 22316363 ↗ Feb 2012 |
| Target | MST1R | “Macrophage-stimulating protein receptor inhibitor” CHEMBL601719 ↗ |